Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps

References

• Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):1–4. doi: 10.1016/j.jaci.2018.08.022.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437–449. doi: 10.1111/bjd.19574.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Efficacy and safety of nemolizumab in subjects with moderate-to-severe atopic dermatitis. NCT03985943 [accessed 2023 Feb 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT03985943
   Google Scholar
• Clinicaltrials.gov. Evaluation of the efficacy and safety of lebrikizumab (LY3650150) in moderate to severe atopic dermatitis (ADvocate2). NCT04178967 [accessed 2023 Feb 14]. [Available from: https://clinicaltrials.gov/ct2/show/NCT04178967
   Google Scholar
• Sanofi. Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis. Paris and Tarrytown (NY): Sanofi; 2023; [accessed 2023 Apr 3]. Available from: www.sanofi.com/en/media-room/press-releases/2023/2023-03-21-06-00-00-2630956
   Google Scholar
• Clinicaltrials.gov. Tralokinumab monotherapy for children with moderate-to-severe atopic dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1). NCT05388760 [accessed 2023 Feb 14]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT05388760
   Google Scholar
• Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10356):908–919. doi: 10.1016/S0140-6736(22)01539-2.
   PubMed Web of Science ®Google Scholar
• Paller AS, Blauvelt A, Soong W, et al. Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial. J Skin. 2022;6(2):s29. doi: 10.25251/skin.6.supp.s29.
   Google Scholar
• Ruperto N, Lovell DJ, Berman A, et al. Patient-reported outcomes among patients ages two to seventeen years with polyarticular-course juvenile idiopathic arthritis treated with subcutaneous abatacept: two-year results from an international phase III study. Arthritis Care Res. 2023;75(8):1804–1814. doi: 10.1002/acr.24989.
   Web of Science ®Google Scholar
• Ruperto N, Brunner HI, Ramanan AV, et al. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Rheumatology. 2021;60(10):4568–4580. doi: 10.1093/rheumatology/keab047.
   PubMed Web of Science ®Google Scholar
• Giancane G, Papa R, Vastert S, et al. Anakinra in patients with systemic juvenile idiopathic arthritis: long-term safety from the pharmachild registry. J Rheumatol. 2022;49(4):398–407. doi: 10.3899/jrheum.210563.
   PubMed Web of Science ®Google Scholar
• Corredores J, Vofo B, Amer R. Uveitis in children: the role of biological agents in its management. Biomedicines. 2023;11(2):629. doi: 10.3390/biomedicines11020629.
   PubMed Web of Science ®Google Scholar
• Zhuang L, Chen J, Yu J, et al. Dosage considerations for canakinumab in children With periodic fever syndromes. Clin Pharmacol Ther. 2019;106(3):557–567. doi: 10.1002/cpt.1302.
   PubMed Web of Science ®Google Scholar
• Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23(8):943–947. doi: 10.1634/theoncologist.2018-0028.
   PubMed Web of Science ®Google Scholar
• Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi: 10.1016/S0140-6736(20)31286-1.
   PubMed Web of Science ®Google Scholar
• von Kobyletzki L, Svensson Å, Apfelbacher C, et al. Factors that predict remission of infant atopic dermatitis: a systematic review. Acta Derm Venereol. 2015;95(4):389–394. doi: 10.2340/00015555-1941.
   PubMed Web of Science ®Google Scholar
• de Graaf M, Janmohamed SR, Schuttelaar M, et al. Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a delphi consensus project mapping expert opinion in Northern Europe. J Eur Acad Dermatol Venereol. 2022;36(11):2153–2165. doi: 10.1111/jdv.18410.
   PubMed Web of Science ®Google Scholar
• Patel NU, D’Ambra V, Feldman SR. Increasing adherence with topical agents for atopic dermatitis. Am J Clin Dermatol. 2017;18(3):323–332. doi: 10.1007/s40257-017-0261-5.
   PubMed Web of Science ®Google Scholar
• Spekhorst LS, Bakker D, Drylewicz J, et al. Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis. Allergy. 2022;77(11):3398–3407. doi: 10.1111/all.15439.
   PubMed Web of Science ®Google Scholar
• Deleuran M, Thaci D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82(2):377–388. doi: 10.1016/j.jaad.2019.07.074.
   PubMed Web of Science ®Google Scholar
• Sørensen K, Skirbekk H, Kvarstein G, et al. I don’t want to think about it: a qualitative study of children (6-18 years) with rheumatic diseases and parents’ experiences with regular needle injections at home. Pediatr Rheumatol Online J. 2021;19(1):8. doi: 10.1186/s12969-021-00495-4.
   PubMed Web of Science ®Google Scholar
• Gilmore H, Jones S, Monagle P, et al. Investigating the experience of parents who have given their infants enoxaparin at home. Thromb Res. 2022;214:16–20. doi: 10.1016/j.thromres.2022.03.024.
   PubMed Web of Science ®Google Scholar
• Smaldone A, Ritholz MD. Perceptions of parenting children with type 1 diabetes diagnosed in early childhood. J Pediatr Health Care. 2011;25(2):87–95. doi: 10.1016/j.pedhc.2009.09.003.
   PubMed Web of Science ®Google Scholar
• Flokstra-de Blok B, Kocks J, Wouters H, et al. Perceptions on home-administration of biologics in the context of severe asthma: an international qualitative study. J Allergy Clin Immunol Pract. 2022;10(9):2312.e2–2323.e2. doi: 10.1016/j.jaip.2022.04.015.
   Web of Science ®Google Scholar
• Willemsen H, Chowdhury U, Briscall L. Needle phobia in children: a discussion of aetiology and treatment options. Clin Child Psychol Psychiatry. 2002;7(4):609–619. doi: 10.1177/1359104502007004012.
   Google Scholar
• Achten R, Bakker D, Ariens L, et al. Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract. 2021;9(3):1389e2–1392 e2. doi: 10.1016/j.jaip.2020.09.042.
   Web of Science ®Google Scholar
• Pagan AD, David E, Ungar B, et al. Dupilumab improves clinical scores in children and adolescents with moderate to ­severe atopic dermatitis: a real-world, single-center study. J Allergy Clin Immunol Pract. 2022;10(9):2378–2385. doi: 10.1016/j.jaip.2022.06.014.
   PubMed Web of Science ®Google Scholar
• Achten RE, Bakker DS, van Luijk CM, et al. Ocular surface disease is common in moderate-to-severe atopic dermatitis patients. Clin Exp Allergy. 2022;52(6):801–805. doi: 10.1111/cea.14127.
   PubMed Web of Science ®Google Scholar
• Spencer EA, Dolinger MT, Dubinsky MC. A single-center experience with dupilumab for atopic or psoriasiform dermatitis in patients with inflammatory bowel disease. Dig Dis Sci. 2023;68(4):1121–1124. doi: 10.1007/s10620-022-07684-5.
   PubMedGoogle Scholar
• Shimodaira Y, Takahashi S, Iijima K. Anti-IL-4Ralpha monoclonal antibody dupilumab mimics ulcerative colitis: a case report. BMC Gastroenterol. 2021;21(1):207. doi: 10.1186/s12876-021-01803-8.
   PubMed Web of Science ®Google Scholar
• Bridgewood C, Wittmann M, Macleod T, et al. T helper 2 IL-4/IL-13 dual blockade with dupilumab Is linked to some emergent T helper 17–type diseases, including seronegative arthritis and enthesitis/enthesopathy, but not to humoral autoimmune diseases. J Invest Dermatol. 2022;142(10):2660–2667. doi: 10.1016/j.jid.2022.03.013.
   PubMed Web of Science ®Google Scholar
• Casale F, Nguyen C, Dobry A, et al. Dupilumab-associated psoriasis and psoriasiform dermatitis in patients with atopic dermatitis. Australas J Dermatol. 2022;63(3):394–397. doi: 10.1111/ajd.13846.
   PubMed Web of Science ®Google Scholar
• Spekhorst LS, van der Rijst LP, de Graaf M, et al. Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients. Allergy. 2023;78(3):875–878. doi: 10.1111/all.15591.
   PubMed Web of Science ®Google Scholar
• Spekhorst LS, de Graaf M, van der Rijst LP, et al. The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis. Clin Transl Allergy. 2023;13(1):e12219.
   PubMed Web of Science ®Google Scholar
• Gertosio C, Licari A, De Silvestri A, et al. Efficacy, immunogenicity, and safety of available vaccines in children on biologics: a systematic review and meta-analysis. Vaccine. 2022;40(19):2679–2695. doi: 10.1016/j.vaccine.2022.03.041.
   PubMed Web of Science ®Google Scholar
• Jansen MHA, Rondaan C, Legger GE, et al. EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021. Ann Rheum Dis. 2023;82(1):35–47. doi: 10.1136/annrheumdis-2022-222574.
   PubMed Web of Science ®Google Scholar